FDA opens compassionate path to investigational pancreatic cancer drug
The FDA has approved an expanded-access protocol for the investigational pancreatic cancer drug daraxonrasib, allowing eligible patients with metastatic pancreatic ductal adenocarcinoma to access it before full approval. In clinical data, patients taking daraxonrasib showed a median survival of about 13 months versus six months with chemotherapy, and supporters like former Sen. Ben Sasse have reported improved pain and tumor shrinkage. The 300 mg daily pill works by blocking a signal that drives cancer growth, and the FDA’s April 30 protocol approval aims to give seriously ill patients earlier access while trials continue.
